Avacta Group make significant progress with its highly scalable lateral flow test (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins us to discuss its update on the lateral flow rapid antigen test. Alastair reminds us of the COVID-19 tests that it is developing, talks us through the key points of todays update, progress made with the other tests taking the first preCISION pro drug programme into the clinic and what other updates we can expect.

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISION™ tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK.

The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100 billion. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.

The company’s pre|CISION targeted chemotherapy platform, releases active chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thereby improving the overall safety and therapeutic potential of these powerful anti-cancer treatments.

By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta Group expects to take its first drug, a pre|CISION targeted form of the standard-of-care doxorubicin, into the clinic in early 2021.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

CORRECTION: Clarification Regarding Medusa 19 Antibody Test

DirectorsTalk would like to highlight that the article from TheBusinessdesk.com has now been deleted and DirectorsTalk would also like to mention that Avacta is not involved in the antibody test produced by Medusa 19. Avacta Group

Avacta Group Plc

More detail on the SARS-CoV-2 ELISA laboratory test

Alastair Smith gives more detail on their latest announcement that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19. Avacta Group Plc

Avacta Group Plc

Avacta signs new deal for Covid-19 testing

Wetherby-based Avacta, in partnership with therapeutic giant Cytiva, is developing a rapid test strip for patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the

Avacta Group Plc

Avacta’s partnership with ADC Therapeutics: In detail

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. What is the objective of the collaboration: The partnership will aim at the development of

Avacta Group Plc

Thanks a billion as LG Chem broadens deal with Avacta

Avacta Group could earn anything from $1/2bn to $1bn from an extended partnership with LG Chem Life Science, the Massachusetts-based subsidiary of the South Korean LG Group. The windfall stems from additional drug development programmes utilising

Avacta Group Plc

Avacta Group and LG Chem Life Sciences expand partnership

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences, the life sciences division of the South Korean LG

Avacta Group Plc

BBI appointed to manufacture saliva-based COVID-19 test

South Wales based BBI develops and manufactures raw materials and finished test products for the in-vitro diagnostics market with manufacturing sites in five different countries, spanning four continents. Dr. Mario Gualano, chief executive of BBI Group, said: “BBI are

Avacta Group Plc

Avacta Group Q&A: Demand for coronavirus test to be very high (LON:AVCT)

Avacta Group’s Alistair Smith discusses BBI Solutions as a manufacturing partner, the performance of the prototype with Cytiva, expanding their contract with Daewoong Pharmaceutical and the progress of the COVID-19 test with Adeptrix in this exclusive interview with DirectorsTalk.

Avacta Group Plc

Avacta Group appoints Neil Bell as Chief Development Officer

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect. Neil will be responsible for late stage pre-clinical